← Eichor
Study identifier: NCT05832489 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders

Condition: Adult ADHD · Adult-onset ADHD With Mood Disorder  ·  Sponsor: University Hospital, Strasbourg, France

PhasePhase 3
Planned participants80
Who can joinAll sexes, 18 Years to 60 Years
Healthy volunteersYes

About this study

Attention Deficit Hyperactivity Disorder (ADHD) in adults is a common psychiatric disorder, with important consequences in terms of quality of life, mental health (associated disorders and poorer response to treatment), family life, risk of accidents; with a consequent cost for society. Adult ADHD is frequently associated with psychiatric co-morbidities, and notably associated with mood disorders (major depressive disorder or bipolar disorder) in about 50% of cases. The diagnosis of ADHD in adults is made in patients with an attentional complaint (pure ADHD or ADHD-P), but also very often in the management of a comorbid mood disorder (ADHD associated with mood disorder, or ADHD-MD). In this case, the ADHD had no impact during childhood and adolescence. Medication management is well established for ADHD-P, and medication is based on methylphenidate, which has a rapid and significant effect on attentional symptoms and impulsivity. However, in the case of ADHD-HD, there is little evidence of treatment efficacy and the mechanisms of action of methylphenidate at the brain level are poorly understood. The aim of the study is to determine the neural mechanisms of the effect of methylphenidate, using functional MRI and EEG, in ADHD-P and ADHD-HD patients, and to compare them to healthy subjects. A single dose allows us to observe effects that are then persistent with repeated doses. The aim is to determine, by means of a biomarker, whether methylphenidate treatment responds to th…

This description comes directly from the study's public registry record.

Talk to the study team

Sébastien WEIBEL, MD  ·  33388115157  ·  sebastien.weibel@chru-strasbourg.fr

Hélène SOAVELO  ·  33388116559  ·  helene.soavelo@chru-strasbourg.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Service de Psychiatrie 2, Hôpitaux Universitaires de StrasbourgStrasbourg, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05832489